Last reviewed · How we verify
Docetaxel followed by anthracycline and cyclophosphamide
Docetaxel followed by anthracycline and cyclophosphamide is a Small molecule drug developed by Xijing Hospital. It is currently FDA-approved.
At a glance
| Generic name | Docetaxel followed by anthracycline and cyclophosphamide |
|---|---|
| Sponsor | Xijing Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2)
- Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer (PHASE2, PHASE3)
- Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer (PHASE2)
- Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (PHASE2)
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (PHASE3)
- Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel followed by anthracycline and cyclophosphamide CI brief — competitive landscape report
- Docetaxel followed by anthracycline and cyclophosphamide updates RSS · CI watch RSS
- Xijing Hospital portfolio CI
Frequently asked questions about Docetaxel followed by anthracycline and cyclophosphamide
What is Docetaxel followed by anthracycline and cyclophosphamide?
Docetaxel followed by anthracycline and cyclophosphamide is a Small molecule drug developed by Xijing Hospital.
Who makes Docetaxel followed by anthracycline and cyclophosphamide?
Docetaxel followed by anthracycline and cyclophosphamide is developed and marketed by Xijing Hospital (see full Xijing Hospital pipeline at /company/xijing-hospital).
What development phase is Docetaxel followed by anthracycline and cyclophosphamide in?
Docetaxel followed by anthracycline and cyclophosphamide is FDA-approved (marketed).